Valera | Caperna | Onkaido | Elpidera

At Moderna, we believe the world needs novel, innovative approaches to address both known and future infectious disease threats. Focused exclusively on the advancement of mRNA-based vaccines and therapies for the prevention and treatment of infectious diseases, our venture Valera is at the forefront of advancing this innovation. 

The Valera team is currently leveraging two of Moderna’s therapeutic modalities, intramuscular vaccines and intravenous (IV) systemic therapeutics, to advance its drug candidates.

Moderna’s mRNA vaccine technology offers potential advantages in efficacy, speed of development, and production scalability and reliability, which may position our company as a leader in preparing for and responding to infectious disease threats that place millions of people at risk around the world.

Formed in 2014, Valera has advanced seven viral vaccine programs from discovery to development candidate nomination, with two Phase 1 studies involving Valera-developed mRNA-based vaccines currently underway. These vaccines span a spectrum of infectious diseases, none of which has an approved treatment or vaccine.

Valera is also utilizing Moderna’s IV systemic therapeutics modality to advance the development of a combination of mRNA-based antibody therapeutics to help prevent human immunodeficiency virus (HIV) infection through a partnership with the Bill & Melinda Gates Foundation.